Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARASLE: GS-0272 in Rheumatoid Arthritis
NCT06031415Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of GS-0272 in rheumatoid arthritis (RA) (4 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Adverse Events, Percentage of Participants Experiencing Serious Adverse Events and 4 more. Started Sep 2023; status: terminated.
02
Drugs
GS-0272
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06031415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031415.